home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 09/16/19

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - Next Super Stock conference presenters: CYDY, MDCL, HOTH, NEXCF delivering results, and positioned for transformational growth in coming months

NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has recently published published CEO Interviews, video presentations, and news updates from the company’s presenting at last month’s NEXT SUPER STOCK Live! inves...
CYDY - CytoDyn on go with mid-stage study of PRO 140 in colorectal cancer

The FDA has signed off on a Phase 2 clinical trial evaluating CytoDyn's ( OTCQB:CYDY +0.2% ) leronlimab (PRO 140), combined with Bayer's Stivarga (regorafenib), in patients with metastatic colorectal cancer (mCRC). More news on: CytoDyn Inc., Healthcare stocks news, Read more ...

CYDY - CytoDyn Announces FDA Clearance to Proceed with Phase 2 Study of Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer

VANCOUVER, Washington, Sept. 09, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, a...

CYDY - CytoDyn Announces Webcast for its Annual Meeting of Stockholders

VANCOUVER, Washington, Sept. 06, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, a...
CYDY - CytoDyn Files an IND and a Phase 2 Protocol with the FDA for the Treatment of NASH with Leronlimab

VANCOUVER, Washington, Sept. 04, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, a...

CYDY - CytoDyn to Present at RHK Capital 2019 Disruptive Growth Conference

VANCOUVER, Washington, Aug. 29, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, an...

CYDY - CytoDyn Joins The Stock Day Podcast to Discuss Phase 3 Trials for Their HIV Program

Phoenix, Arizona--(Newsfile Corp. - August 22, 2019) - The Stock Day Podcast welcomed CytoDyn (OTCQB: CYDY) ("the Company"), a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CC...
CYDY - CytoDyn's PRO 140 shows sustained effect in HIV study

Updated results from an HIV clinical trial evaluating escalating doses of CytoDyn's ( OTCQB:CYDY -0.1% ) PRO 140 (leronlimab) showed sustained viral load suppression at ~one year. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...

CYDY - Wall Street Reporter presents: "Next Super Stock - Live!" August 15, 2019

NEW YORK, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Wall Street Reporter will be hosting the “Next Super Stock - Live !” livestream online-only investor conference on Thursday August 15, 2019 from 12:00PM-1:00PM EST. Registration is free. Click here to join:  https://www.wall...

CYDY - CytoDyn Provides Update on Dose Escalating Trial with Leronlimab for HIV Monotherapy for a Potential Pivotal Trial

564 patients have been enrolled in monotherapy trials to date with over 150 patients hitting the benchmark of one-year of sustained viral suppression The response rate post-10 weeks of monotherapy is 68% with 350 mg dose, 94% with 525 mg and 85% with 700 mg VANCOUVER, Washington, Aug....
Previous 10 Next 10